Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Biotechnology

Healthcare
$7.06 -2.70%

-$0.26 today

Market cap
$618.50M
Beta
2.00
P/E (TTM)
-5.1
EPS (TTM)
-$1.80
52W Low $4.02High $36.26

Volume 1.18M

Average 1.27M

OLMA Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Olema Pharmaceuticals, Inc.NASDAQ: OLMA

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 74.5% from a year ago

Net receivables stood at $3.35M at the end of Q1 FY2026, up 74.5% from a year earlier and down 17.4% from the prior quarter. Over 3 fiscal years it compounded at +133.4% a year.

Context

  • Net receivables amounted to 0.6% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +74.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.35M-17.4% QoQ
Last fiscal yearDec 2025
$4.06M+91.3% YoY
Year agoMar 2025
$1.92M+74.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+74.5%——
1 year+91.3%——
3-year CAGR+133.4%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
4.06M USD
Year-over-year change
+91.3%
4-year CAGR
+136.3%

Net Receivables vs competitors

How OLMA compares with its peers on the latest reported figures

  • OLMA's Mar 2026 net receivables of $3.35M is the lowest of the 2 companies compared; the peer median is $26.33M.
  • Its year-over-year change of +74.5% is the highest of 2, against a peer median of +4.6%.
  • Net receivables amounts to 0.6% of total assets for OLMA, versus a peer median of 13.7%.
OLMA Competitors Peer median
Net Receivables for OLMA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PBYIPuma Biotechnology, Inc.Mar 2026$26.33M +4.6%+8.3%13.7%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$3.35M +74.5%+133.4%0.6%
Peer median (excluding OLMA) $26.33M+4.6%+8.3%13.7%

Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents13.81M23.7M68.54M139.48M48.3M
Short-term Investments273.44M180.72M193.27M294.61M457.14M
Net Receivables130K319K673K2.12M4.06M
Inventory00000
Other Current Assets01.52M1.68M366K1.59M
Total Current Assets290.69M208.9M266.51M438.47M515.45M
Property, Plant & Equipment (Net)4.72M3.98M3.26M2.06M1.15M
Goodwill00000
Intangible Assets000683K0
Long-term Investments00000
Tax Assets00000
Other Non-current Assets540K2.77M7.17M9.76M16.83M
Total Non-current Assets5.26M6.75M10.43M12.51M17.98M
Total Assets295.95M215.65M276.95M450.98M533.43M
Account Payables23K374K2.7M4.46M9.25M
Short-term Debt0001.17M1.12M
Tax Payables88K68K73K41K0
Deferred Revenue00000
Other Current Liabilities3.96M4.6M5.47M30.31M32.02M
Total Current Liabilities9.02M16.55M21.62M41.76M51.8M
Long-term Debt000069K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00003M
Total Non-current Liabilities2.36M1.55M1.43M257K3.07M
Total Liabilities11.38M18.1M23.05M42.02M54.87M
Common Stock3K3K4K6K8K
Retained Earnings(104.19M)(208.98M)(305.63M)(435.11M)(597.56M)
Accumulated OCI(149K)(1.81M)347K143K621K
Other Stockholders Equity00000
Minority Interest00000
Total Equity284.57M197.55M253.9M408.96M478.56M
Total Debt3.29M2.57M2.42M1.43M1.19M
Net Debt(10.52M)(21.14M)(66.12M)(138.05M)(47.11M)

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Intrinsic Alpha fair value

Locked

Current Price

$7.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.